Abstract | BACKGROUND: METHODS: We retrospectively identified 3512 primary TJAs (2344 total hip arthroplasties and 1168 total knee arthroplasties) with ASA used as VTE chemoprophylaxis between 2000 and 2019. Patients received ASA twice daily for 4-6 weeks after surgery with 961 (27%) receiving low-dose ASA and 2551 (73%) receiving regular-dose ASA. The primary endpoint was 90-day incidence of symptomatic VTEs. Secondary outcomes were gastrointestinal (GI) bleeding events and mortality. The mean age at index TJA was 66 years, 54% were female, and mean body mass index was 31 kg/m2. The mean Charlson Comorbidity Index was 3.5. Mean follow-up was 3 years. RESULTS: There was no difference in 90-day incidence of symptomatic VTEs between low-dose and regular-dose ASA (0% vs 0.1%, respectively; P = .79). There were no GI bleeding events in either group. There was no difference in 90-day mortality between low-dose and regular-dose ASA (0.3% vs 0.1%, respectively; P = .24). CONCLUSION: In 3512 primary TJA patients treated with ASA, we found a cumulative incidence of VTE <1% at 90 days. Although this study is underpowered, it appears that twice daily low-dose ASA was equally effective to twice daily regular-dose ASA for VTE chemoprophylaxis, with no difference in risk of GI bleeds or mortality. LEVEL OF EVIDENCE: III, retrospective cohort study.
|
Authors | Mason E Uvodich, Matthew P Siljander, Michael J Taunton, Tad M Mabry, Kevin I Perry, Matthew P Abdel |
Journal | The Journal of arthroplasty
(J Arthroplasty)
Vol. 36
Issue 7
Pg. 2359-2363
(07 2021)
ISSN: 1532-8406 [Electronic] United States |
PMID | 33640184
(Publication Type: Journal Article)
|
Copyright | Copyright © 2021 Elsevier Inc. All rights reserved. |
Chemical References |
|
Topics |
- Anticoagulants
- Arthroplasty, Replacement, Hip
(adverse effects)
- Aspirin
- Female
- Humans
- Retrospective Studies
- Venous Thromboembolism
(epidemiology, etiology, prevention & control)
|